Analysts increased scrutiny of Biogen’s lupus drug litifilimab ahead of pivotal Phase 3 readouts, pressing executives on late-stage trial strategy and pipeline confidence amid a broader turnaround effort led by CEO Chris Viehbacher. The questioning highlights how investors are weighing evidence rigor and the commercial implications of Phase 3 outcomes. The coverage points to an environment where late-stage de-risking is demanding more granular explanations, including how trial designs, endpoints, and potential patient selection could influence results. It also signals heightened sensitivity to whether a single program can meaningfully shift the company’s pipeline trajectory. For the lupus competitive set, the key signal is that Biogen’s next data events are likely to shape near-term expectations around efficacy and tolerability benchmarks in late-stage immunology development.